Nabendu Pore

Title: The Innovative Contributions of Nabendu Pore

Introduction

Nabendu Pore is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of binding molecules that target specific proteins associated with various diseases.

Latest Patents

Nabendu Pore holds 2 patents, with his latest focusing on binding molecules specific for ASCT2 and their uses. This patent discloses ASCT2-binding molecules, such as anti-ASCT2 antibodies and their antigen-binding fragments. These molecules can be conjugated to cytotoxic drugs, forming ASCT2 antibody-drug conjugates (ADCs). The anti-ASCT2 antibodies can be derived from hybridoma technology, resulting in murine monoclonal antibodies and their humanized versions. These binding molecules are designed to specifically target cells that express ASCT2, allowing for internalization into these cells. The patent also outlines methods for diagnosing and treating diseases characterized by ASCT2 overexpression, including certain types of cancer, and provides innovative approaches for cancer treatment using ASCT2 ADCs.

Career Highlights

Nabendu Pore is currently associated with Medimmune Limited, where he continues to advance his research and development efforts. His work has been instrumental in the field of therapeutic antibodies, contributing to the understanding and treatment of various cancers.

Collaborations

Nabendu has collaborated with notable colleagues, including Martin Borrok, III and Emil F Michelotti. These collaborations have further enhanced the impact of his research in the biotechnology sector.

Conclusion

Nabendu Pore's innovative work in developing ASCT2-binding molecules showcases his commitment to advancing medical science and improving treatment options for cancer patients. His contributions are a testament to the importance of research and innovation in the field of biotechnology.